Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

eating major global health problems despite it occurring outside of the traditional windows for the flu, we are working diligently to provide a solution as it is expected that the disease may become even more virulent later this year during the traditional flu season."

The reason why the L.E.A.P.S. technology lends itself to creating a much more effective immune therapy against the H1N1 flu virus is because the L.E.A.P.S. conjugates induce an effective and powerful immune response without causing excessive amounts of pro-inflammatory cytokines. In the case of prior pandemic influenza, such as the "Spanish Influenza" and more recently the "Avian Flu", patients with stronger immune systems had a greater chance of dying because their immune response was too strong (too many pro-inflammatory cytokines). This is called a cytokine storm. While normally many cytokines play a key role in preventing and treating swine flu, in some cases excessive cytokine amounts may exacerbate the disease as it appears that, unlike the normal flu which affects the very young and very old most severely, swine flu may be more like the avian flu which hits people in their prime more severely.

In addition, LEAPS conjugates may be used to potentially overcome the virus' mutations by focusing on more conserved and common epitopes critical for critical viral function.

The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... Adding to their already extensive selection of ... – Buy 2 of any Weighing Boats or Dishes ... technicians looking for durable and reliable weighing products to ... applications including weighing liquids, solid, or granulated samples. ... hexagonal, square, aluminum weighing, and standard boats. Aluminum weighing ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2
... March 23, 2011 Advanced Cell Technology, Inc. ("ACT"; ... in the field of regenerative medicine, announced today that ... Company,s patent application to provide broad intellectual property protection ... retinal pigment epithelial (RPE) cells from human embryonic stem ...
... of survival tend to favor the strongest, but University ... world of self-healing materials, it is the somewhat frail ... Langmuir a new model laying out the ... particles that can regenerate after taking damage and are ...
... NEOG ) announced today that its net income ... 28, increased 27% from the previous year to $4,943,000 — ... $0.17 per share. Third quarter revenues increased ... company, compared to the prior year,s $33,833,000. Year to date, ...
Cached Biology Technology:ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Only the weak survive?: Pitt team adds more give for stronger self-healing materials 2Neogen Reports 27% Increase in Quarterly Net Income 2Neogen Reports 27% Increase in Quarterly Net Income 3Neogen Reports 27% Increase in Quarterly Net Income 4Neogen Reports 27% Increase in Quarterly Net Income 5Neogen Reports 27% Increase in Quarterly Net Income 6
(Date:7/30/2014)... Antonio Life Sciences Institute (SALSI), a joint venture between ... The University of Texas Health Science Center at San ... Pilot Program. The winners, Emily Boice from UTSA and ... $25,000 for their project titled, "Novel engineered ferritins for ... , Boice and Huang,s research is focused on finding ...
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... PHILADELPHIA The second American Association for Cancer ... Research: From the Laboratory to the Clinic provides attendees ... in a variety of fields, including the tumor microenvironment, ... takes place March 7-10, 2010, at the King Hussein ...
... of America is pleased to announce the 2010 Yeast ... at the University of British Columbia (UBC) in Vancouver, ... various aspects of eukaryotic biology in yeast. Program ... Canadian astronaut who is also a Member of Parliament. ...
... Texas Imagine a mosquito-borne virus that has already infected ... Asia, the islands of the Indian Ocean, Africa and northern ... that can linger for months or even years. It,s capable ... much of North America. And no vaccine or treatment exists ...
Cached Biology News:The AACR to host second cancer research conference in Jordan 22010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Experimental vaccine protects monkeys against chikungunya 2
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
... consists of AmnioMAX-C100 Basal ... and AmnioMAX-C100 Supplement (Cat. ... complete with antibiotics and ... requires no further supplementation ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to Parathyroid Hormone Receptor ... tested applications). Antigen: ... extracellular amino acids 99-116 of Human ... Entrez Gene ID: 5746 ...
Biology Products: